Evidence map›Paper›PMID 32337660›Full record

ReviewClinical pharmacokinetics2020

Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.

Daryl J Fediuk, Gianluca Nucci, Vikas Kumar Dawra, David L Cutler, Neeta B Amin, Steven G Terra, Rebecca A Boyd, Rajesh Krishna, Vaishali Sahasrabudhe

2 registry-linked trialsOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical pharmacokinetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00989079 phase1completednot on this map

A Phase 1 Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of PF-04971729 After Administration of Single Escalating Oral Doses Under Fed and Fasted Conditions in Healthy Volunteers

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2009 to 2009Enrolled24ConditionsType 2 Diabetes MellitusArmsErtugliflozin, Placebo to Ertugliflozin
NCT01018823 phase1completednot on this map

A Phase 1, Randomized, Placebo-Controlled, Parallel Group, 14 Day Repeated Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-04971729 In Otherwise Healthy Overweight And Obese Adult Subjects

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2009 to 2010Enrolled40ConditionsHealthy VolunteerArmsErtugliflozin, Placebo to Ertugliflozin
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Is boosting OXPHOS/FAO gene pathways the final end-mechanism of SGLT2i protection?Journal of molecular and cellular cardiology plus · 2025
    Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Daryl J FediukPfizer Inc., 445 Eastern Point Road, Groton, CT, 06340, USA.
Gianluca NucciPfizer Inc., 1 Portland St, Cambridge, MA, 02139, USA.
Vikas Kumar DawraPfizer Inc., 235 E 42nd St, New York, NY, 10017, USA.
David L CutlerMerck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ, 07033, USA.
Neeta B AminPfizer Inc., 1 Portland St, Cambridge, MA, 02139, USA.
Steven G TerraPfizer Inc., 1 Burtt Rd, Andover, MA, 01810, USA.
Rebecca A BoydPfizer Inc., 445 Eastern Point Road, Groton, CT, 06340, USA.
Rajesh KrishnaMerck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ, 07033, USA.
Vaishali SahasrabudhePfizer Inc., 445 Eastern Point Road, Groton, CT, 06340, USA. Vaishali.Sahasrabudhe@pfizer.com.
Pfizer (United States) · USMerck & Co., Inc., Rahway, NJ, USA (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ertugliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), is approved in the US, EU, and other regions for the treatment of adults with type 2 diabetes mellitus (T2DM). This review summarizes the ertugliflozin pharmacokinetic (PK) and pharmacodynamic data obtained during phase I clinical development, which supported the registration and labeling of this drug. The PK of ertugliflozin was similar in healthy subjects and patients with T2DM. Oral absorption was rapid, with time to peak plasma concentrations (T

Indexed as

Diabetes Mellitus, Type 2AdultBridged Bicyclo Compounds, HeterocyclicHumansHypoglycemic AgentsSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsBridged Bicyclo Compounds, HeterocyclicertugliflozinHypoglycemic AgentsSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID32337660
PMCPMC7403171
OpenAlexW3018574880

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.